Drug Approval | March 01, 2022
USFDA approves CITI Biopharma’s Vonjo
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Subscribe To Our Newsletter & Stay Updated
